Clinical Trial Update: Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients [EARLY_Phase 1]

View source ↗

Summary

This clinical trial update outlines a safety and efficacy evaluation of LX111 gene therapy for neovascular age-related macular degeneration, currently in EARLY …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• LX111

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Neovascular Age-related Macular Degeneration | EARLY_Phase 1 | Status: RECRUITING